Keio-backed Neusignal raises ¥5.32B to take Alzheimer's pill to US trials
What's the deal? Tokyo-based Neusignal Therapeutics has raised 5.32 billion yen (≈$32.9 million) in a Series B round led by the Keio Innovation InitiativeDealroom has a profile for this one. Try Dealroom → (KII).
The cash will fund Phase 1b clinical trials in the US for an oral Alzheimer's drug aimed directly at patients.
Why now? Neusignal plans to begin the US trial in summer 2026, after early studies in healthy adults showed promising safety, tolerability, and pharmacokinetic results.
KII, which backs startups built on research from Keio University, is doubling down on a venture it already funds. The firm launched Japan's first university-led impact fund, the KII3 Impact Fund, in October 2023.
Neusignal, founded in April 2022 under chief executive officer Tatsu ArimotoDealroom has a profile for this one. Try Dealroom →, develops treatments for dementia and mental disorders.
What could go wrong? Phase 1b is still early. Many Alzheimer's drugs fail in later trials, and the field faces ongoing debate over treatment costs and the risk-benefit balance.
Recent approved drugs slow progression but require clinical administration. Neusignal's pitch — an oral, low-molecular-weight pill taken at home — must still prove it works in patients, not just healthy volunteers.
The signal: Now at breakout stage, Neusignal exemplifies how Japan's university spinouts are scaling into clinical-stage biotech, with KII — an investment fund spun out of Keio University — deepening its bet on academic research as a route to tackling big social problems. An at-home Alzheimer's pill could ease caregiver burdens and cut healthcare costs in an ageing society; the race is now to prove it in the clinic.
Read more: Third News
Image credit: frankieleon
